Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Kappos L., Bates D., Edan G., Eraksoy M., Garcia-Merino A., Grigoriadis N., ...Daha Fazla

LANCET NEUROLOGY, cilt.10, sa.8, ss.745-758, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 10 Sayı: 8
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1016/s1474-4422(11)70149-1
  • Dergi Adı: LANCET NEUROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.745-758
  • İstanbul Üniversitesi Adresli: Evet

Özet

Natalizumab, a highly specific alpha 4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.